Redundancies announced at Stevenage’s GlaxoSmithKline

PUBLISHED: 08:30 17 April 2019

Redundancies are being made at GlaxoSmithKline as part of a new approach to research and development.

Redundancies are being made at GlaxoSmithKline as part of a new approach to research and development.

Archant

Redundancies are being made at pharmaceutical giant GlaxoSmithKline in Stevenage as part of “a new approach to research and development”.

A spokesman for GSK on the Gunnels Wood Road site said “a small number of roles will be directly impacted”.

She said: “Since we announced our new approach to research and development in 2018, the future direction of our portfolio has become clearer, prioritising innovation and moving towards delivering a pipeline of transformational medicines with a focus on immunology, genetically validated targets, and finding platforms and technologies that amplify our science.

“We have identified where changes are necessary to ensure we can fully support our evolving pipeline priorities. We anticipate a small number of roles will be directly impacted by these changes but continue to expect GSK's R&D operations to grow overall with increased investment.”


If you value what this story gives you, please consider supporting the Comet. Click the link in the orange box above for details.

Become a supporter

This newspaper has been a central part of community life for many years. Our industry faces testing times, which is why we're asking for your support. Every contribution will help us continue to produce local journalism that makes a measurable difference to our community.

Latest from the The Comet